MedTrace Logo

Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection

NCT01328158 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 236

Last updated 2014-12-22

Study results available
· View outcomes & findings →

Summary

This study of Kaletra (Lopinavir (LPV)/Ritonavir (RTV)) tablets will be conducted to clarify the following with regard to treatment with this drug:

1. Incidence and conditions of occurrence of adverse reactions in the clinical setting
2. Factors that may affect the safety and effectiveness of Kaletra (QD)

Conditions

  • Human Immunodeficiency Virus Infection

Sponsors & Collaborators

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • Susumu Adachi, MD · AbbVie G.K.

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01328158 on ClinicalTrials.gov